SARS2 / Covid19

Collection of information related to Covid19

Get Started. It's Free
or sign up with your email address
SARS2 / Covid19 by Mind Map: SARS2 / Covid19

1. Clinical Characteristics, Comorbidities, and Outcomes Among Patients With COVID-19 Hospitalized in the NYC Area

2. Prevention

2.1. Social distancing

2.1.1. Self imposed

2.1.2. State imposed

2.2. Prevention Strategies

2.2.1. Disinfection

2.2.1.1. Alcohol Based

2.2.1.2. Hydrogen Peroxide

2.2.1.2.1. Vapor phase

2.2.1.3. Chlorine Based

2.2.1.3.1. Na Hypochlorite

2.2.1.4. Non contact

2.2.1.4.1. UV light

2.2.1.4.2. Negative Ions

2.2.1.5. EPA - Surface Disinfectants - List N

2.2.1.5.1. List N: Disinfectants for Use Against SARS-CoV-2 | US EPA

2.2.2. Boost Immunity

2.2.2.1. BCG vaccine

2.2.2.1.1. https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus

2.2.2.1.2. Pharmaceutical Technology: BCG vaccination may induce heterologous immunity and protect against Covid-19. https://www.pharmaceutical-technology.com/comment/bcg-vaccination-covid-19/

2.2.2.2. Convalescent Plasma

2.2.2.3. Nutrition / Sleep / Exercise

2.2.2.4. Vitamin D ?

2.2.2.4.1. https://youtu.be/GCSXNGc7pfs

2.2.2.4.2. https://www.ncbi.nlm.nih.gov/pubmed/32252338

2.2.2.4.3. https://clinicaltrials.gov/ct2/show/NCT04334005

2.2.2.4.4. https://www.hopkinsmedicine.org/health/wellness-and-prevention/vitamin-d-and-calcium

2.2.2.4.5. https://www.medrxiv.org/content/10.1101/2020.04.08.20058578v3

2.2.3. Personal Hygiene

2.2.4. Contact Tracing

2.2.4.1. https://www.npr.org/sections/health-shots/2020/04/21/840539685/cdc-to-fund-650-health-experts-to-help-states-trace-stop-covid-19

2.3. Immunization

2.3.1. Vaccine

2.3.1.1. J & J

2.3.1.1.1. https://www.forbes.com/sites/thomasbrewster/2020/03/30/the-us-just-signed-a-450-million-coronavirus-vaccine-contract-with-johnson--johnson/

2.3.1.2. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins

2.3.1.2.1. Phase 1 Kaiser

2.3.1.3. PittCoVacc

2.3.1.3.1. https://www.independent.co.uk/news/science/coronavirus-vaccine-pittsburgh-university-lancet-study-covid-pandemic-a9442536.html

2.3.1.4. Chadox1

2.3.1.4.1. https://www.vaccitech.co.uk/technology/

2.3.1.4.2. http://www.ox.ac.uk/news/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage#

2.3.1.4.3. Timeline

2.3.1.4.4. Phase i/ii

2.3.1.5. mRNA

2.3.1.5.1. Moderna

2.3.1.5.2. Summer Phase III Trials

2.3.1.6. CanSino

2.3.1.6.1. https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2400DZ

2.3.1.6.2. Phase ii

2.3.1.7. CoVaxin (Bharat Biotech)

2.3.1.7.1. https://theprint.in/health/all-about-bharat-biotechs-covaxin-indias-first-indigenous-covid-vaccine-candidate/455028/

2.3.2. Convalescent Plasma

2.3.2.1. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds

2.3.2.2. JHU - Immunization of Healthcare Workers - http://foxbaltimore.com/news/coronavirus/fda-approves-trial-for-coronavirus-therapy-at-johns-hopkins-university

2.3.2.3. Antibody Titres in Convalescent Plasma

2.3.2.3.1. https://www.medrxiv.org/content/10.1101/2020.06.08.20124792v1

2.3.2.4. D614G Mutation and reduced antisera neutralization

2.3.2.4.1. https://www.biorxiv.org/content/10.1101/2020.06.20.161323v1

2.3.3. What is immunity

2.3.3.1. Immune System: Innate and Adaptive Immunity Explained

2.3.3.2. T cell Mediated

2.3.3.2.1. https://directorsblog.nih.gov/2020/07/28/immune-t-cells-may-offer-lasting-protection-against-covid-19/

2.4. LAV

2.4.1. https://theprint.in/health/in-a-first-india-us-pharma-majors-join-hands-to-develop-covid-19-vaccine/397334/

2.5. Nutrition - As anti inflammatory

2.5.1. https://www.mdpi.com/2072-6643/12/5/1466/htm

2.5.1.1. Vit D / C + Zinc + Fiber

2.6. Seroconversion = Immunity?

2.6.1. https://www.medrxiv.org/content/10.1101/2020.05.19.20101832v2

3. Treatment

3.1. Symptomatic

3.1.1. ARDS or Atypical ARDS

3.1.1.1. Ventilators

3.1.1.1.1. Low cost ventilators

3.1.1.1.2. General Motors

3.1.1.2. O2 hoods

3.1.1.2.1. https://erj.ersjournals.com/content/early/2020/04/16/13993003.01017-2020

3.1.2. GI

3.1.3. Non-ARDS

3.2. Pharmacological

3.2.1. Anti-virals

3.2.1.1. Favipiravir

3.2.1.1.1. https://fortune.com/2020/03/28/coronavirus-treatment-drug-antiviral-favipiravir-avigan-fujifilm/

3.2.1.1.2. Link to Chinese study?

3.2.1.2. Remdesivir

3.2.1.2.1. https://www.fiercebiotech.com/biotech/gilead-supersizes-remdesivir-trials-changes-primary-endpoint

3.2.1.2.2. SoC according to Fauci as of 4/29

3.2.1.3. Lopinavir? Probably Not?

3.2.1.3.1. https://theprint.in/health/hiv-drug-combo-touted-as-a-promising-covid-19-treatment-fails-clinical-trial/405959/

3.2.2. HCQ / Chloroquine

3.2.2.1. FDA Emergency Authorization - https://www.politico.com/news/2020/03/29/fda-emergency-authorization-anti-malaria-drug-155095

3.2.2.2. Haem metabolism

3.2.2.2.1. https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173

3.2.2.3. IHU - Mediterranean Infection

3.2.2.3.1. Pré-Prints IHU – IHU

3.2.2.4. VA Study - Contraindicated in those over 70?

3.2.2.4.1. https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf

3.2.3. Others

3.2.3.1. Azithromycin

3.2.4. ACE2 Receptor Blockers?

3.2.4.1. http://www.infectioncontroltoday.com/covid-19/evidence-continues-link-ace-inhibitors-severe-covid-19-symptoms

3.2.4.2. How to treat those with hypertension?

3.2.4.3. Jacob Glanville on LinkedIn: #COVID19 #therapeutic #neutralizing | 103 comments

3.2.4.4. ACE2 Receptor

3.2.4.4.1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=AGTR1&keywords=ACE2,Receptor

3.2.5. hsp90 inhibition?

3.2.5.1. Drug Repositioning Suggests a Role for the Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection

3.2.5.2. What else inhibits hsp90?

3.2.5.2.1. curcumin

3.2.6. TMPRSS2 Inhibition

3.2.6.1. https://www.dpz.eu/en/home/single-view/news/die-vermehrung-von-sars-coronavirus-2-im-menschen-verhindern.html

3.2.6.2. Genetic Expression of ..

3.2.6.2.1. https://www.medrxiv.org/content/10.1101/2020.03.30.20047878v1.full.pdf

3.2.7. Anti-coagulants

3.2.7.1. https://www.eurekalert.org/pub_releases/2020-05/tmsh-btm050420.php

3.2.8. Ivermectin?

3.2.8.1. https://www.sciencedirect.com/science/article/pii/S0166354220302011

3.2.8.2. Ivermectin and Doxy being used in Bangladesh

3.2.9. IL-6 Inhibition

3.2.9.1. https://www.technologyreview.com/2020/06/03/1002650/antibody-drug-tocilizumab-immune-response-covid-19-saves-lives/

3.3. Immunological

3.3.1. Convalescent Plasma

3.3.1.1. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds

3.3.1.2. https://jamanetwork.com/journals/jama/fullarticle/2763983

3.3.1.3. https://www.bizjournals.com/philadelphia/news/2020/04/06/montco-firm-forms-alliance-to-develop-coronavirus.html

3.3.1.4. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma

3.3.1.5. Michigan State Convalescent Plasma Project

3.3.1.5.1. National COVID-19 Convalescent Plasma Project

3.3.1.5.2. Key Scientific Papers

3.3.1.6. FDA Recommendations

3.3.1.6.1. Investigational COVID-19 Convalescent Plasma - Emergency INDs

3.3.2. Monoclonal Antibodies

3.3.2.1. https://www.npr.org/sections/health-shots/2020/03/26/822003826/how-monoclonal-antibodies-might-prove-useful-against-the-coronavirus

3.3.3. Immunomodulators

3.3.3.1. Sepsivac / India

3.3.3.1.1. CSIR to test sepsis drug in asymptomatic Covid patients and those who have recovered

3.4. Stem Cells?

3.4.1. Miomir's LI Post

3.4.1.1. https://www.linkedin.com/posts/miomir-knezevic-5a79613_novel-approach-to-treating-terminal-stage-activity-6648598562789736450-nePZ

3.5. Nutrition

3.5.1. Clinical Considerations

3.5.1.1. Pg 30 - Handbook of Covid-19 Prevention and Treatment, Zhejiang University School of Medicine.

3.5.1.1.1. Prevention of Regurgitation and Aspiration - Gastric residual volume and gastrointestinal function should be routinely evaluated. Appropriate enteral nutrition is recommended to be given as earlier as possible. Nasointestinal feeding and continuous nasogastric decompression are recommended. Enteral nutrition should be suspended and aspiration with 50 mL syringe be done before transfer. If no contraindication exists, a 30° semi-sitting position is recommended

3.5.1.1.2. Fluid Management - Excessive fluid burden worsens hypoxemia in COVID-19 patients. To reduce pulmonary exudation and improve oxygenation, the amount of fluid should be strictly controlled while ensuring the patient's perfusion.

3.5.1.1.3. GI Considerations

3.6. WHO Solidarity Trial

3.6.1. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments

4. Diagnosis / Management

4.1. Clinical

4.1.1. Symptoms

4.1.1.1. Disease Progression

4.1.1.1.1. Comorbidities

4.1.1.2. Cardiac

4.1.1.2.1. https://khn.org/news/mysterious-heart-damage-not-just-lung-troubles-befalling-covid-19-patients/

4.1.1.3. Expanded Case Definition

4.1.1.3.1. The Washington Post: CDC confirms six coronavirus symptoms showing up in patients over and over. https://www.washingtonpost.com/health/2020/04/27/six-new-coronavirus-symptoms/

4.1.2. Where all do we have ACE2 Receptors?

4.1.2.1. Angiotensin-converting enzyme 2 - Wikipedia

4.1.2.2. Lungs

4.1.2.3. Heart

4.1.2.4. Arteries

4.1.2.5. Intestines

4.1.2.6. Where else?

4.1.2.7. Inhibition

4.1.2.7.1. rhACE2?

4.1.2.8. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes

4.1.2.9. It's ok to continue BP medication

4.1.2.9.1. https://jamanetwork.com/journals/jama/fullarticle/2767669

4.1.3. Signs

4.1.3.1. Red itchy eyes / conjunctivitis

4.1.4. Tests / Biomarkers of severe disease

4.1.4.1. https://pubmed.ncbi.nlm.nih.gov/32286245/

4.1.5. Pathophysiology

4.1.5.1. URTI

4.1.5.2. LRTI

4.1.5.2.1. CT Lung https://www.ncbi.nlm.nih.gov/pubmed/?term=32053470

4.1.5.2.2. Type L / Type H Pneumonia?

4.1.5.2.3. CPAP vs BiPAP (information)

4.1.5.2.4. Breathing mechanics

4.1.5.3. GI

4.1.5.3.1. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30083-2/fulltext

4.1.5.4. Cardiac / Lung / Kidney

4.1.5.4.1. https://www.ahajournals.org/doi/10.1161/JAHA.120.016219

4.1.5.5. ARDS

4.1.5.5.1. How accurate are the Phenotypes?

4.1.5.6. Atypical ARDS?

4.1.5.6.1. https://www.youtube.com/watch?v=U5cvPwh_vtM&t=8s

4.1.5.6.2. Hypoxemia

4.1.5.6.3. See also HCQ Bubble

4.1.5.6.4. Different phenotypes - Italian experience

4.1.5.7. Coagulopathies / DIC?

4.1.5.7.1. Coagulation Abnormalities in COVID 19 Patients

4.1.5.7.2. Why?

4.1.5.8. Microangiopathy in the lung

4.1.5.8.1. https://www.nejm.org/doi/full/10.1056/NEJMoa2015432?query=C19&cid=DM92296_Catalyst_Subscriber&bid=201860269

4.1.5.9. Derm

4.1.5.9.1. Covid Toes

4.1.5.10. ACE2 Mediated Vascoconstriction?

4.1.5.10.1. A Theoretical Model of the Pathophysiology of COVID-19 with Farid Jalali

4.1.5.11. HR monitors

4.1.5.11.1. https://www.medscape.com/viewarticle/934496

4.1.6. Risk Factors

4.1.6.1. https://pubmed.ncbi.nlm.nih.gov/32232218/

4.1.6.2. Comorbidities

4.1.7. COVID-19 | Corona Virus: Epidemiology, Pathophysiology, Diagnostics

4.1.7.1. As of March 15th

4.1.8. NEJM

4.1.8.1. https://www.nejm.org/coronavirus

4.1.8.2. Case Study - Long Term Health Care Facility - Washington State

4.1.8.2.1. https://www.nejm.org/doi/full/10.1056/NEJMoa2005412?cid=DM89287_Catalyst_COVID-19_Newsletter&bid=174243764

4.1.9. Lancet

4.1.10. Predisposition to severe disease symptoms

4.1.10.1. https://jamanetwork.com/journals/jamacardiology/fullarticle/2763845

4.1.10.2. Inflammation as a modifier?

4.1.10.2.1. Any correlations with hs-CRP?

4.1.11. Social Determinants

4.1.11.1. https://www.beckershospitalreview.com/data-analytics/ucsf-launches-dashboard-to-track-how-social-determinants-affect-population-health.html

4.1.11.2. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2020.00598?utm_campaign=HASU+5-24-20&utm_medium=email&utm_content=COVID-19%3A+Disparities+In+Outcomes%2C+Primary+Care%2C+Remdesivir%3B+ACA+Round-Up%3B+Health+Insurance+Surcharges+For+Tobacco+Use%3B+Reimagining+Involuntary+Commitment&utm_source=Newsletter

4.1.11.2.1. Why are people of color disproportionately susceptible to severer outcomes?

4.1.12. MMWR June 16

4.1.12.1. https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm

4.2. Testing

4.2.1. NAAT

4.2.1.1. RT-PCR

4.2.1.1.1. N Segment

4.2.1.1.2. Other segments

4.2.1.1.3. https://youtu.be/C1t3SoR8fwg

4.2.1.2. IIT Probe less Dx - https://www.linkedin.com/posts/activity-6647392190601539584-zv0l - POC

4.2.2. Serological

4.2.2.1. IgM

4.2.2.2. IgG

4.2.3. ALT predictor of severe lung complications?

4.2.3.1. https://www.france24.com/en/20200330-ai-tool-predicts-which-coronavirus-patients-get-deadly-wet-lung

4.2.3.2. https://en.wikipedia.org/wiki/Alanine_transaminase

4.2.4. CRISPR

4.2.4.1. India

4.2.4.1.1. Feluda - https://theprint.in/science/satyajit-rays-feluda-will-soon-detect-coronavirus-in-minutes-thanks-to-csir-scientists/404057/

4.2.5. Rapid Biosensor S Korea

4.2.5.1. https://pubs.acs.org/doi/10.1021/acsnano.0c02823

5. Data Sources

5.1. JHU

5.1.1. https://coronavirus.jhu.edu/

5.1.2. Github

5.1.2.1. https://github.com/CSSEGISandData/COVID-19

5.2. FDA Covid FAQs

5.2.1. Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions

5.3. The Covid Handbook - China

5.3.1. PDF

5.4. Prevalence

5.4.1. NYC

5.4.1.1. https://www.nejm.org/doi/full/10.1056/NEJMc2009316?fbclid=IwAR1JU20xBGOuad0UDREUjGb1Kpj1VQ0ypbkwL_GheeFr15rvREpxEwuSBqg

5.4.1.1.1. "Of the 211 women without symptoms, all were afebrile on admission. Nasopharyngeal swabs were obtained from 210 of the 211 women (99.5%) who did not have symptoms of Covid-19; of these women, 29 (13.7%) were positive for SARS-CoV-2. Thus, 29 of the 33 patients who were positive for SARS-CoV-2 at admission (87.9%) had no symptoms of Covid-19 at presentation."

5.4.2. Santa Clara County

5.4.2.1. COVID-19 Antibody Seroprevalence in Santa Clara County, California

5.4.2.1.1. "Under the three scenarios for test performance characteristics, the population prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%)."

5.5. Napkin iFR

5.5.1. Preliminary CFR - Covid

5.6. California

5.6.1. https://public.tableau.com/views/COVID-19PublicDashboard/Covid-19Public?:embed=y&:display_count=no&:showVizHome=no

5.7. YouTube

5.7.1. covid - YouTube

5.8. Case Definition CDC April 14th

5.8.1. Coronavirus Disease 2019 (COVID-19) in the U.S.

5.8.2. To include Probable Cases and Probable Deaths

5.8.3. CDC Cases in the US

5.8.3.1. Coronavirus Disease 2019 (COVID-19) in the U.S.

5.9. R Packages and Shiny Apps

5.9.1. https://towardsdatascience.com/top-5-r-resources-on-covid-19-coronavirus-1d4c8df6d85f

5.9.1.1. Covid19 DataHub

5.9.1.1.1. covid19datahub/COVID19

5.10. CDC

5.10.1. Scenario Planning

5.10.1.1. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html

5.11. UC Clinical

5.11.1. https://www.healthcareitnews.com/news/uc-health-creates-unified-data-set-aid-covid-19-researchers

5.12. Mobility and Case Numbers

5.12.1. https://transportfindings.org/article/12976-using-google-community-mobility-reports-to-investigate-the-incidence-of-covid-19-in-the-united-states

5.13. Excess Mortality

5.13.1. https://ourworldindata.org/covid-excess-mortality

6. Models / Literature

6.1. Italian SIDR Model

6.1.1. Data-based analysis, modelling and forecasting of the COVID-19 outbreak

6.2. DoD Model for information evolution

6.2.1. https://www.pnas.org/content/117/11/5664

6.3. IHME

6.3.1. https://covid19.healthdata.org/united-states-of-america

7. Epidemiological Concepts

7.1. R0 (Reproductive Ratio)

7.1.1. Basic Reproduction Number, R0

7.2. Stages of Spread

7.3. SIR Model

7.3.1. https://youtu.be/Qrp40ck3WpI

7.3.2. https://youtu.be/uSLFudKBnBI

8. Patient Flow

8.1. I'm having difficulty breathing

8.1.1. emergency.fyi

8.1.2. Kaiser

8.2. I have symptoms

8.2.1. CDPH

8.2.1.1. California Department of Public Health

8.3. Monitor Pulse Ox Levels

8.3.1. Cutoff?

8.3.1.1. 90%?

8.3.1.2. 95%?

9. Legend

9.1. Anecdotal

9.2. Re-purposed Approaches

9.3. Hypotheses

9.4. Adjuvants

9.5. In development

9.6. Very Important

10. Equipment

10.1. PPE

10.1.1. Facial Masks

10.1.1.1. Reusable

10.1.1.1.1. Elastomeric

10.1.1.1.2. Non soiled N95

10.1.1.2. Disposable

10.1.1.2.1. Surgical

10.1.1.2.2. N95

10.1.2. Shields

10.1.3. Gowns

10.1.4. Gloves

10.1.5. Booties

10.1.6. Suits

10.1.7. PAPR - Another bottle neck

10.1.7.1. A must for invasive ventilation?

10.1.8. Suppliers - PPE / Serology Tests

10.1.8.1. Global - Sourced From China

10.1.8.1.1. Prices as of March 27th

10.1.8.2. Local India PPE / Sanitizer

10.1.8.2.1. [email protected]

10.2. Ventillators

10.3. Plasmaphaeresis

10.4. CPAP

10.4.1. Italy

10.4.1.1. CPAP with Helmets

10.4.1.1.1. https://www.uchicagomedicine.org/forefront/patient-care-articles/helmet-based-ventilation-is-superior-to-face-mask-for-patients-with-respiratory-distress

10.4.2. What is CPAP?

10.4.2.1. What's the Difference Between a CPAP, APAP, and BiPAP Machine?

11. Virus Morphology

11.1. Mutation

11.1.1. https://youtu.be/FYPZHA-UjUY

11.1.2. Antigenic Shift - Influenza

11.1.2.1. https://youtu.be/tMTl3gU0mFc

11.1.3. Tracking the different strains

11.1.3.1. https://nextstrain.org/

11.1.4. India

11.1.4.1. No need to panic, COVID-19 is something we can easily conquer: Padma Bhushan Dr D Nageshwar Reddy  

11.1.5. Super virulent strains?

11.1.5.1. https://www.scmp.com/news/china/science/article/3080771/coronavirus-mutations-affect-deadliness-strains-chinese-study

11.1.6. S1 D614G

11.1.6.1. https://www.biorxiv.org/content/10.1101/2020.04.29.069054v2

11.2. Replication Cycle

11.2.1. https://youtu.be/zvuYJTL90J8

11.3. Coronaviruses

11.3.1. Coronaviruses 101: Focus on Molecular Virology

11.4. Seasonality?

11.4.1. https://www.cidrap.umn.edu/news-perspective/2020/04/experts-covid-19-pandemic-unlikely-ebb-weather-warms

11.5. ReplicationKinetics

11.5.1. Kinetic Modeling of Virus Growth in Cells

12. Idea Hacking

12.1. https://docs.google.com/document/d/1rVz-GPtF2ek-8V2sZcZPPfL6ocXqtCUEWFEwiDp-7_Y/edit?usp=drivesdk

12.2. MUSC Mask w/ HEPA

12.2.1. https://web.musc.edu/innovation/covid-19-innovation

12.3. Czech Face Shield Design

12.3.1. https://www.prusa3d.com/covid19/

13. Surveillance

13.1. Waste Water

13.1.1. https://www.bloomberg.com/news/articles/2020-03-31/coronavirus-in-sewage-portended-covid-19-outbreak-in-dutch-city

13.2. Recurrence?

13.2.1. Can you get re-infected with coronavirus?

13.3. Santa Clara Study

13.4. NY maternity Study

13.5. India's Delhi Food Worker Study

13.6. NY City Surveillance

14. Disaggregate News Reports

14.1. https://theprint.in/health/pancreatitis-drug-trials-to-a-wastewater-test-for-tracking-virus-top-research-on-covid-19/391990/

15. Questions / Hypotheses

15.1. Is genetic diversity more resilient to developing severe forms of covid19 at a population level?

15.2. Virus particles are small - they replicate fast - as part of replication they damage cells - they then enter adjacent cells - they basically over time will make their own access route. It seems some strains replicate faster than other ones, and so they will be the ones I'm guessing that are causing more of the non lung / non intestinal issues?

15.3. Background inflammation relevant? hsCRP?

15.4. Nicotine / Smoking?

15.4.1. https://theprint.in/health/nicotine-patch-test-on-covid-patients-healthcare-workers-to-see-if-smokers-are-protected/413513/

16. India

16.1. The Bhilwara Model

16.1.1. https://www.mohfw.gov.in/pdf/3ContainmentPlanforLargeOutbreaksofCOVID19Final.pdf

16.2. National Covid Trajectory

16.2.1. National Covid Trajectory - India

17. Italy

17.1. Vo

17.1.1. https://www.medrxiv.org/content/10.1101/2020.04.17.20053157v1

18. How to Protect MeS Individuals?

19. Milestones

19.1. 4/30

19.1.1. Korea confirms reinfections aren't taking place

19.1.2. Remdesivir becomes SoC in the US

19.1.2.1. Next step is Remdesivir + Monoclonal Antibodies